{
    "title": "Valeant predicts tough 2017 with revenue to decline",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-4267556/Valeant-Pharmas-profit-beats-expectations.html",
    "date": "2017-02-28",
    "keywords": [
        "year",
        "business",
        "percent",
        "debt",
        "share",
        "humer",
        "dermatology",
        "treatment",
        "investor",
        "growth",
        "bausch",
        "amp",
        "company",
        "month",
        "loss",
        "revenue",
        "ankur",
        "banerjeefeb",
        "inc",
        "tuesday",
        "transition",
        "drug",
        "price",
        "pressure",
        "prescriptionsvaleant",
        "model",
        "specialty",
        "pharmacy",
        "philidor",
        "toenail",
        "fungus",
        "jublia",
        "option",
        "cut",
        "pressurenow",
        "deal",
        "alliance",
        "care",
        "volume",
        "gastrointestinal",
        "purchase",
        "salix",
        "period",
        "august",
        "sale",
        "dendreon",
        "cancer",
        "skincare",
        "purposevaleant",
        "wider",
        "profit",
        "interest",
        "lomb",
        "eyecare",
        "trading",
        "close",
        "helm",
        "executive",
        "joseph",
        "papa",
        "confidence",
        "investigation",
        "accounting",
        "pricing",
        "practicesit",
        "management",
        "outlook",
        "analyst",
        "irina",
        "research",
        "notelaval",
        "valeant",
        "scrutiny",
        "heart",
        "quarter",
        "estimate",
        "thomson",
        "york",
        "banerjee",
        "bengaluru",
        "editing",
        "sai",
        "ravikumar",
        "andrea",
        "ricci"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}